Insel Gruppe AG

The sponsor is active in childhood stroke research, particularly focal cerebral arteriopathy, an inflammatory vessel wall disease linked to infection. The therapeutic emphasis is on preventing progression of arterial narrowing and reducing the risk of recurrent cerebrovascular events in children.

• Inflammatory arteriopathy
• Childhood ischemic stroke
• Anti-inflammatory treatment

Clinical interest also includes the interaction between vascular inflammation and stroke outcome in the pediatric setting.

Trial activity covers isolated subsegmental pulmonary embolism, with focus on the balance between clinical surveillance and anticoagulation in low-risk patients. The research addresses recurrence prevention while considering bleeding risk and treatment intensity.

• Subsegmental pulmonary embolism
• Venous thromboembolism
• Anticoagulation strategy

This area reflects interest in refining management for smaller clot burden disease within pulmonary vascular medicine.

Research includes patients with atrial fibrillation who have undergone percutaneous coronary intervention and stent implantation. The therapeutic domain centers on antithrombotic treatment choices that address both cardiac and cerebral ischemic risk while limiting bleeding complications.

• Antithrombotic therapy
• Percutaneous coronary intervention
• Stent-related care

Attention is directed toward treatment strategies for patients requiring long-term anticoagulant management after coronary revascularization.